During the COVID-19 Public Health Emergency, the Drug Enforcement Agency (DEA) acted swiftly to waive the in-person requirement for the prescription of controlled substances to ensure millions of both established and new patients were able to receive prescriptions via telehealth. Unfortunately, once the PHE concludes the in-person requirement goes back into place, leaving many patients with nowhere to turn and many will end up with delayed or no care, and negative outcomes.

Given that the COVID-19 PHE is renewed in 90-day increments and could end as early as the beginning of 2023, and that the Special Registration proposed rules have not yet been published and will take additional time to finalize once they are, it is imperative that the DEA has a plan to ensure that patients do not lose access to necessary treatment and medications in the interim.

Please sign this stakeholder letter, co-led by the American Association of Child and Adolescent Psychiatry, the American Psychiatric Association, the American Telemedicine Association, and ATA Action urging the DEA to act and outlining multiple short-term actions the DEA could take immediately to ensure millions of patients are able to continue receiving treatment where and when they need it until the promulgation of the Special Registration for Telemedicine Rules.

Your organization's signature is requested by COB Wednesday, November 9.

You can find a PDF version of the letter here: https://drive.google.com/file/d/1XDejkKRdmubYUD1d-IeWFefab2r2RAwg/view?usp=sharing

**NOTE: This letter is open to organizational signatories only. Please do not complete this form if you are not authorized to sign on behalf of your organization.